Imaging Ductal Carcinoma In Situ in the Era of De-Escalation: Role, Limits, and Clinical Implications for Risk-Adapted Management
The widespread implementation of population-based mammographic screening has markedly increased the detection of ductal carcinoma in situ (DCIS), without a proportional reduction in breast cancer-specific mortality. This divergence has intensified concerns regarding overdiagnosis and overtreatment and has prompted increasing interest in treatment de-escalation and active surveillance strategies. Breast imaging remains indispensable for DCIS detection, extent assessment, and longitudinal monitoring. However, although imaging features correlate with histopathologic risk factors at the population level, their ability to predict individual biological progression is inherently probabilistic and limited. Overinterpretation of imaging phenotypes as surrogates of invasive destiny risks inappropriate reassurance or unjustified therapeutic escalation, particularly in the context of high-sensitivity modalities that may overestimate disease extent or trigger additional interventions without proven outcome benefits. This review examines the modality-specific roles of mammography, ultrasound, breast magnetic resonance imaging (MRI), contrast-enhanced mammography (CEM), and emerging artificial intelligence (AI) approaches within contemporary DCIS management, with particular attention to their implementation in active surveillance trials such as LORIS, COMET, LORD, and LORETTA. Across modalities, imaging primarily reflects lesion morphology, spatial distribution, and vascular behaviour, and functions most reliably as a risk-filtering and safety-gating instrument aimed at excluding radiologically unsafe scenarios, including occult invasion, underestimated disease extent, or imaging evolution incompatible with continued observation. By delineating both the capabilities and the epistemological limits of imaging, this review proposes a structured clinical decision framework in which imaging supports-but does not independently determine-risk-adapted management. Disciplined integration of imaging into multidisciplinary decision-making is essential to enable safe de-escalation, prevent false reassurance, and align DCIS care with patient-centred and value-based principles.
Authors
- Francesca Caumo (ORCID: https://orcid.org/0000-0002-9457-5176)
- Gianluca Gatta (ORCID: https://orcid.org/0000-0003-0874-8294)
- Lanfranco Musto
- Marcella Buono
- Lucia Pilati
- Luigi Schiavone
- Sighelgaita Rizzo
Institutions
- Istituto Oncologico Veneto (IT)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- University of Campania "Luigi Vanvitelli" (IT)
Publication Details
- Journal
- Diagnostics
- Published
- 2026-03-05
- DOI
- https://doi.org/10.3390/diagnostics16050776
- Primary Topic
- MRI in cancer diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00